Abdominal Wall Transplant
Primary Purpose
Transplant;Failure,Kidney, Transplant; Failure, Liver, Transplant; Failure, Bowel
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Abdominal Wall Transplant with another solid organ transplant
Abdominal Wall Transplant alone
Sponsored by
About this trial
This is an interventional treatment trial for Transplant;Failure,Kidney focused on measuring Research, Transplant, Abdominal Wall, Hernia
Eligibility Criteria
Inclusion Criteria:
- Candidates between 18-65 years old
- Willingness and legal ability to give consent
- Abdominal Wall in combination with another organ transplant: they must be eligible for the non-vascularized composite allograft organ transplant at Duke
Exclusion Criteria:
- Malignancy at evaluation or history of malignancy that precludes transplantation
- Pregnancy: Women who are of childbearing potential must have a negative serum pregnancy test within 48 hours of transplant and agree to use reliable contraception with two contraceptive methods for a minimum of 2 years following abdominal wall transplantation. Subjects seeking to become pregnant following 2 years will be made aware during the consent process that the effect of pregnancy on the transplanted abdominal wall and vice versa is unknown.
- Medical exclusion criteria for general anesthesia
- Ongoing substance abuse or history of untreated substance abuse
Sites / Locations
- Duke University Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Isolated Abdominal Wall Transplant
Abdominal Wall with Solid Organ Transplant
Arm Description
Outcomes
Primary Outcome Measures
Number of subjects with a viable abdominal wall transplant at 18 months
Secondary Outcome Measures
Full Information
NCT ID
NCT03310905
First Posted
October 11, 2017
Last Updated
January 24, 2023
Sponsor
Duke University
Collaborators
Linda Cendales, MD, Kadiyala Ravindra, M.D., Detlev Erdmann, M.D.
1. Study Identification
Unique Protocol Identification Number
NCT03310905
Brief Title
Abdominal Wall Transplant
Official Title
Abdominal Wall Transplantation for the Reconstruction of Abdominal Wall Defects as Adjunct to Abdominal Solid Organ Transplantation
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 1, 2018 (Actual)
Primary Completion Date
January 1, 2028 (Anticipated)
Study Completion Date
June 1, 2028 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University
Collaborators
Linda Cendales, MD, Kadiyala Ravindra, M.D., Detlev Erdmann, M.D.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this protocol is to determine the safety and efficacy of abdominal wall transplantation as a treatment for the reconstruction of abdominal wall defects. Abdominal wall transplantation may be performed alone or in combination with another transplant.
Detailed Description
Within this protocol we propose to perform abdominal wall transplantation in 5 subjects, either as an isolated abdominal wall or in combination with another organ transplant. Each subject will be followed for a study period of 18 months.
Participants receiving an isolated abdominal wall or abdominal wall in combination with another organ transplant will receive the standard immunosuppression therapy as the non-vascularized composite allograft organ transplant. These patients will be studied to determine efficacy of the abdominal wall transplant to restore function of the defective abdominal wall for a study period of 18 months at Duke University Medical Center.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Transplant;Failure,Kidney, Transplant; Failure, Liver, Transplant; Failure, Bowel, Abdominal Wall Defect, Abdominal Wall Fistula, Abdominal Wall Hernia, Abdominal Wall Injury
Keywords
Research, Transplant, Abdominal Wall, Hernia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
5 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Isolated Abdominal Wall Transplant
Arm Type
Experimental
Arm Title
Abdominal Wall with Solid Organ Transplant
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
Abdominal Wall Transplant with another solid organ transplant
Intervention Description
Transplant of abdominal wall in combination with another solid organ transplant.
Intervention Type
Procedure
Intervention Name(s)
Abdominal Wall Transplant alone
Intervention Description
Abdominal Wall Transplant alone
Primary Outcome Measure Information:
Title
Number of subjects with a viable abdominal wall transplant at 18 months
Time Frame
up to 18 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Candidates between 18-65 years old
Willingness and legal ability to give consent
Abdominal Wall in combination with another organ transplant: they must be eligible for the non-vascularized composite allograft organ transplant at Duke
Exclusion Criteria:
Malignancy at evaluation or history of malignancy that precludes transplantation
Pregnancy: Women who are of childbearing potential must have a negative serum pregnancy test within 48 hours of transplant and agree to use reliable contraception with two contraceptive methods for a minimum of 2 years following abdominal wall transplantation. Subjects seeking to become pregnant following 2 years will be made aware during the consent process that the effect of pregnancy on the transplanted abdominal wall and vice versa is unknown.
Medical exclusion criteria for general anesthesia
Ongoing substance abuse or history of untreated substance abuse
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Linda Cendales, MD
Phone
919-681-7514
Email
linda.cendales@duke.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Kadiyala Ravindra, MD
Phone
919-613-9687
Email
kadiyala.ravindra@duke.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Linda Cendales, MD
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kadiyala Ravindra, MD
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Individual Site Status
Recruiting
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
At this time all data will be de-identified and there is no plan to make individual participant data available to other researchers.
Learn more about this trial
Abdominal Wall Transplant
We'll reach out to this number within 24 hrs